Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive publishing date : 2021 - 04 - 12 save search
Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date March 31, 2021
Published: 2021-04-12 (Crawled : 01:00) - globenewswire.com
NDAQ | $60.075 0.11% 0.11% 2.3M
|
Finance
|
| O: 0.19%
H: 1.05%
C: 0.98%
positive nasdaq
Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines
Published: 2021-04-12 (Crawled : 20:00) - biospace.com/
APDN | $0.3461 3.93% 3.79% 130K
|
Commercial Services
|
| O: -0.42%
H: 10.47%
C: -6.22%
covid positive results vaccine trial
APDN, Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial
Published: 2021-04-12 (Crawled : 18:00) - adnas.com
APDN | $0.3461 3.93% 3.79% 130K
|
Commercial Services
|
| O: -0.42%
H: 10.47%
C: -6.22%
positive results trial
Bit Digital Announces North American Executive Team Headquartered in New York, Positions for Rapid Growth
Published: 2021-04-12 (Crawled : 13:00) - prnewswire.com
BTBT | $1.925 6.35% 5.97% 4.4M
|
Finance
|
| O: 2.59%
H: 3.28%
C: -12.64%
growth positive
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
Published: 2021-04-12 (Crawled : 13:00) - biospace.com/
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 1.57%
H: 5.08%
C: -6.62%
lung cancer gene therapy positive therapy cancer collaboration preclinical pre-clinical
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
Published: 2021-04-12 (Crawled : 13:00) - biospace.com/
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: 0.0%
H: 0.11%
C: -8.71%
covid phase 2 positive results positive results trial
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
Published: 2021-04-12 (Crawled : 12:15) - globenewswire.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -1.68%
H: 2.54%
C: -5.2%
treatment phase 1 positive cancer trial rtx-321 phase 3 phase 2
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.